“Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies”, says Visiongain report
05 September 2019
Visiongain has launched a new pharma report Small Animal Imaging (In-Vivo) Market Report: By Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes) and Region.
Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies. The global Small Animal Imaging (In-Vivo) market is anticipated to grow at a lucrative CAGR of 11.3% and anticipated to reach USD 3.32 Billion by 2029.
Small animal imaging (In vitro) is a method used in the imaging of biological procedures in living animals that demonstrates changes in cell activity to study drug effects and progression of disease. Small animal imaging is used for drug development and different disease drug evaluation during clinical studies. Small animal imaging includes digital angiography, micro MRI, micro CT, micro SPECT, X-ray imaging and magnetic particle imaging. Small animal (primarily mice) in vivo imaging is increasingly implemented throughout the drug development phase, especially in the therapeutic area of oncology / cancer.
Currently the most widely used imaging modalities are PET, optical (bioluminescence and fluorescence), and MRI. Single modality imaging prevails, with multi-modality presently being accessed primarily through co-registration with other imaging methods for instance PET+CT. In vivo imaging in research studies is anticipated to have the biggest effect on drug development by tracking the progression of disease and therapeutic reaction. The most commonly used reagents in imaging studies are PET tracers (e.g. Fluorine-18 based) and bioluminescent markers / reporters (e.g. luciferins, proluciferins).
North America holds majority of market share followed by Europe. Growth is attributed to rising pre-clinical research, increased public-private investment to promote the manufacturing of radioisotopes, government support for pharmaceutical and biotechnology R&D, and increasing demand for rapid and advanced methods among others. On the other hand, favorable R&D platform and supportive regulatory scenario across Asian economies are stimulating the growth of the small animal imaging market in the region.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as Agilent Technologies, Inc., Aspect Imaging, Berthold Technologies, Bioscan, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Gamma Medica-Ideas, Inc., Genovis Ab, LI-COR Biosciences, Life Technologies Corporation, Mediso Ltd., MILabs B.V., Miltenyi Biotec GmbH, MR Solutions Ltd., PerkinElmer, Inc, Promega Corporation, Inc., Siemens AG, Spectral Instruments Imaging, Thermo Fisher Scientific and Trifoil Imaging among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.